Home9926 • HKG
add
Akeso Inc
Previous close
$139.20
Day range
$137.30 - $141.80
Year range
$60.60 - $179.00
Market cap
129.42B HKD
Avg Volume
8.01M
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
Market news
AOL.com
12 minutes ago
The Nasdaq Has Entered a Correction: Here Are 2 Stocks That Are Can't-Miss Buys
0.30%
Financials
Income Statement
Revenue
Net income
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 822.37M | 49.63% |
Operating expense | 938.87M | 52.33% |
Net income | -271.47M | -96.77% |
Net profit margin | -33.01 | -31.51% |
Earnings per share | — | — |
EBITDA | -214.84M | -69.73% |
Effective tax rate | 0.07% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 9.17B | 24.80% |
Total assets | 16.00B | 25.44% |
Total liabilities | 7.05B | 17.55% |
Total equity | 8.95B | — |
Shares outstanding | 910.55M | — |
Price to book | 14.00 | — |
Return on assets | -4.52% | — |
Return on capital | -5.36% | — |
Cash Flow
Net change in cash
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -271.47M | -96.77% |
Cash from operations | -360.06M | -297.61% |
Cash from investing | -1.19B | -36.22% |
Cash from financing | 1.48B | 26.46% |
Net change in cash | -75.61M | -135.30% |
Free cash flow | 155.33M | 165.49% |
About
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong.
It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
Founded
Mar 19, 2012
Website
Employees
3,761
